Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
J Cosmet Dermatol. 2024 May;23(5):1726-1733. doi: 10.1111/jocd.16192. Epub 2024 Jan 30.
Facial hyperpigmentation can negatively affect an individual's emotional and psychosocial well-being.
Assess safety and tolerability of a combination of microdermabrasion (DG) procedures using a novel brightening pro-infusion serum (EC-DG) with a targeted at-home treatment regimen in subjects with mild to severe facial hyperpigmentation, including melasma, post-inflammatory hyperpigmentation, and dark spots.
PATIENTS/METHODS: This 12-week, open-label study enrolled 18 subjects (Fitzpatrick skin types I-IV) who underwent 6 in-office DG procedures with EC-DG (one procedure administered biweekly), along with daily topical application of a brightening treatment serum and dark spot cream. End points included change from baseline across multiple skin quality attributes and the Melasma Area and Severity Index (MASI), self-assessment questionnaires, and tolerability assessments.
The combination treatment was well tolerated and resulted in significant (p ≤ 0.05) improvements from baseline in radiance, tactile roughness, and moisturization/hydration immediately after the first treatment, in MASI score at day 3, and in overall hyperpigmentation at week 4. Most (94.1%) subjects were satisfied with treatment.
DG procedures using EC-DG combined with a targeted at-home skincare regimen are effective and tolerable for treating facial hyperpigmentation across a broad range of skin types.
面部色素沉着会对个人的情绪和社会心理健康产生负面影响。
评估使用新型焕亮增效导入精华液(EC-DG)联合家庭靶向护肤方案进行微磨削术(DG)处理在轻至重度面部色素沉着(包括黄褐斑、炎症后色素沉着和黑斑)患者中的安全性和耐受性,这些患者的皮肤类型为 Fitzpatrick I-IV 型。
患者/方法:这是一项为期 12 周的开放性研究,共纳入 18 名受试者,他们接受了 6 次 EC-DG 院内 DG 处理(每两周进行一次),同时每日外用焕亮治疗精华液和黑斑霜。终点包括多个皮肤质量属性和黄褐斑面积及严重程度指数(MASI)、自我评估问卷以及耐受性评估自基线的变化。
联合治疗耐受性良好,在首次治疗后即刻、第 3 天的 MASI 评分以及第 4 周的整体色素沉着方面,即刻提亮、触感粗糙度和保湿/水分度均出现有统计学意义(p≤0.05)的改善。大多数(94.1%)受试者对治疗满意。
EC-DG 联合家庭靶向护肤方案的 DG 处理对各种皮肤类型的面部色素沉着均有效且耐受性良好。